Radioligand Therapy in Prostate Cancer Treatment
Prostate cancer has become one of the most significant applications of Radioligand Therapy. Many prostate cancer cells express prostate-specific membrane antigen (PSMA), making it an ideal target for radioligand binding.
In RLT for prostate cancer, PSMA-targeting ligands are labeled with therapeutic radioisotopes. Once administered, these ligands selectively bind to PSMA-expressing tumor cells, delivering radiation directly to the cancer while minimizing impact on healthy tissue.
Radioligand Therapy is often used in advanced or metastatic prostate cancer, particularly in patients who have exhausted conventional treatment options. It can target cancer cells throughout the body, including bone and lymph node metastases.
Patients undergoing RLT may experience symptom relief, reduced tumor burden, and improved disease control. The targeted nature of the therapy allows it to be administered with manageable side effects.
As diagnostic imaging improves, Radioligand Therapy continues to refine its role in prostate cancer management.